Skip to main content
Figure 6 | Molecular Medicine

Figure 6

From: Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule

Figure 6

CD38 expression in ATRA-treated CD19+/CD5+ CLL cells. PBMC isolated from CLL patients (CD38+ CLL, n = 6; CD38− CLL, n = 9) and cultured (24 h at the indicated ATRA concentrations) were stained with anti-CD19, CD5 and CD38 mAbs, all locally produced. CD38 expression was analyzed using FACSDiva software (Becton Dickinson). Representative CD38 expression in CD38+ (A) and CD38− (B) CLL cells from patients treated with ATRA, by evaluating rMFI.

Back to article page

Molecular Medicine

ISSN: 1528-3658